Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.
2.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups..

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

3.

Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis.

Marks SD, Shah V, Pilkington C, Tullus K.

Pediatr Nephrol. 2010 Nov;25(11):2283-8. doi: 10.1007/s00467-010-1605-z.

PMID:
20683619
4.

Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.

Mina R, Abulaban K, Klein-Gitelman MS, Eberhard BA, Ardoin SP, Singer N, Onel K, Tucker L, O'neil K, Wright T, Brooks E, Rouster-Stevens K, Jung L, Imundo L, Rovin B, Witte D, Ying J, Brunner HI.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):195-202. doi: 10.1002/acr.22651.

PMID:
26213987
5.

Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus.

El-Banawy HS, Gaber EW, Maharem DA, Matrawy KA.

J Nephrol. 2012 Jul-Aug;25(4):541-50. doi: 10.5301/jn.5000030.

PMID:
21956768
6.
7.

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis.

Sjöwall C, Zickert A, Skogh T, Wetterö J, Gunnarsson I.

Arthritis Res Ther. 2009;11(6):R188. doi: 10.1186/ar2880.

9.

Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis.

Hung WT, Chen YM, Lan JL, Chen HH, Chen YH, Chen DY, Hsieh CW, Wen MC.

Lupus. 2011 Nov;20(13):1404-10. doi: 10.1177/0961203311417033.

PMID:
21946514
10.

Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.

Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, Kalunian K, Liang MH, Maddison P, Nived O, et al.

J Rheumatol. 1994 Aug;21(8):1468-71.

PMID:
7983648
12.
13.

Urinary mononuclear cell and disease activity of systemic lupus erythematosus.

Chan RW, Lai FM, Li EK, Tam LS, Chung KY, Chow KM, Li PK, Szeto CC.

Lupus. 2006;15(5):262-7.

PMID:
16761499
14.

Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response.

Wang G, Lai FM, Tam LS, Li EK, Kwan BC, Chow KM, Li PK, Szeto CC.

Rheumatology (Oxford). 2009 Jul;48(7):755-60. doi: 10.1093/rheumatology/kep074.

15.

BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.

Yee CS, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Zoma A, Gordon C.

Ann Rheum Dis. 2008 Jun;67(6):873-6.

16.

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Gordon C.

Arthritis Rheum. 2007 Dec;56(12):4113-9.

17.

Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis.

Erdener D, Aksu K, Biçer I, Doğanavşargil E, Kutay FZ.

J Clin Lab Anal. 2005;19(4):172-6.

PMID:
16025478
18.

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D'Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C.

Rheumatology (Oxford). 2005 Jul;44(7):902-6.

19.

Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus.

Yip J, Aghdassi E, Su J, Lou W, Reich H, Bargman J, Scholey J, Gladman DD, Urowitz MB, Fortin PR.

J Rheumatol. 2010 Aug 1;37(8):1667-72. doi: 10.3899/jrheum.091028.

PMID:
20516026
20.

Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.

Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA, Kalunian KC; Systemic Lupus International Collaborating Clinics (SLICC)..

J Rheumatol. 2004 Dec;31(12):2390-4.

PMID:
15570639
Items per page

Supplemental Content

Support Center